$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
奥拉帕尼治疗HER2阴性的转移性乳腺癌
2025-10-19 11:44:20
Check Details
尼拉帕尼治疗遗传性乳腺癌
2025-10-19 11:44:20
Check Details
帕博西尼联合来曲唑联治疗晚期乳腺癌
2025-10-19 11:44:20
Check Details
尼拉帕尼治疗BRCA突变乳腺癌患者
2025-10-19 11:44:20
Check Details
帕博西林+氟维司群治疗乳腺癌
2025-10-19 11:44:20
Check Details
拉帕替尼联合卡培他滨治疗乳腺癌脑转移
2025-10-19 11:44:20
Check Details
卡博替尼治疗转移性乳腺癌的疗效
2025-10-19 11:44:20
Check Details
帕博西尼与来曲唑联合治疗转移性乳腺癌
2025-10-19 11:44:20
Check Details
奥拉帕尼降低晚期乳腺癌死亡风险42%
2025-10-19 11:44:20
Check Details
预防乳腺癌扩散以及转移可服用达沙替尼
2025-10-19 11:44:20
Check Details
哌柏西利+来曲唑治疗晚期乳腺癌
2025-10-19 11:44:20
Check Details
继赫赛汀之后,乳腺癌靶向药又添猛将
2025-10-19 11:44:20
Check Details
1
2
...
1656
1657
1658
1659
1660
1661
1662
...
4158
4159
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Trametinib (Mekinist): Refrigerated Storage, Fasting Administration, and BRAF Mutation Indications Explained
2
Belzutifan (Welireg): HIF-2α Inhibitor for VHL-Associated Tumors and Renal Cell Carcinoma — Dosing Phases, Survival Data, and Efficacy Insights
3
Pemigatinib vs. Anlotinib: Key Differences Between FGFR-Targeted Therapy and Multi-Target Anti-Angiogenic Treatment
4
Lapatinib: A Targeted Anticancer Agent — Not Merely Symptom Relief
5
Lapatinib: Proper Administration Guide and Key Precautions
6
Capivasertib (Truqap) Complete Medication Guide: Indications, Dosing, Safety, and Precautions
7
Cemiplimab Storage and Handling Guide
8
Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Dosing Duration, Efficacy Comparison, and Long-Term Management
9
Belzutifan (Welireg): Comprehensive Guide to the First HIF-2α Inhibitor — Indications, Dosing, and Safety Monitoring
10
Encorafenib (Braftovi): Comprehensive Guide to BRAF V600 Inhibitor Indications, Dose Regimens by Tumor Type, and Administration Requirements
11
Alpelisib vs Inavolisib: How to Choose Between Two PI3Kα Inhibitors in PIK3CA-Mutated Breast Cancer
12
Selumetinib: The First MEK1/2 Inhibitor Approved for Inoperable Plexiform Neurofibromas in NF1